Supplementary Table 1 Current laboratory monitoring recommendations according to the Canada's product monograph for each oral disease-modifying therapy for the treatment of multiple sclerosis.

Oral disease-modifying therapy	**Current recommended monitoring (extracted from Canada's product monograph)**		
	Biochemical liver test	**Lymphocyte count**	**Urinalysis**
Dimethyl fumarate[I]	Prior to initiating treatment with dimethyl fumarate, serum aminotransferase, alkaline phosphatase and total bilirubin levels should be obtained (within 6 months). During treatment, evaluation of transaminases is recommended after 6 months of treatment, then every 6 to 12 months, and as clinically indicated.	Prior to initiating treatment with dimethyl fumarate, obtain a complete blood count, including lymphocytes, if no recent (within 6 months) result is available. A complete blood count, including lymphocytes, is also recommended after 6 months of treatment, then every 6 to 12 months, and as clinically indicated.	Prior to initiating treatment with dimethyl fumarate, urinalysis should be available (within 6 months). During treatment, urinalysis is recommended after 6 months of treatment, then every 6 to 12 months, and as clinically indicated.
Fingolimod[II]	Obtain transaminase and bilirubin levels prior to initiating treatment if no	Obtain a complete blood count before initiating treatment if no recent (i.e. within	Not applicable

	recent (i.e. within the last 6 months) result is available, every 3 months during the first year of treatment and periodically thereafter in the absence of symptoms or when symptoms suggestive of hepatic injury develop.	6 months or after discontinuation of prior therapy) result is available. Treatment with fingolimod should not be initiated when lymphocyte counts are consistently below the normal range.	
Teriflunomide[III]	Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide.	Obtain a complete blood cell count within 6 months before initiating treatment with teriflunomide. Further monitoring should be based on signs and symptoms suggestive of infection.	Not applicable

References:

I. Biogen Canada Inc. TECFIDERA (Dimethyl fumarate delayed-release capsules 120 mg and 240 mg) product monograph [online]. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html.

Accessed August 9, 2019.

II. Novartis Pharmaceuticals Canada Inc. GILENYA (Fingolimod capsules 0.25mg and 0.5 mg) product monograph [online]. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed August 9, 2019.

III. Sanofi Genzyme A Division of Sanofi-Aventis Canada Inc. AUBAGIO (Teriflunomide tablets 14 mg) product monograph [online]. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed August 9, 2019